Video Experimental Relacionado
Updated: Jul 9, 2026
09:46
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Pérdida tardía en el diámetro del lumen y la restenosis binaria para la comparación de stent de eliminación de
Laura Mauri1, E John Orav, Richard E Kuntz
1Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02116, USA. lmauri1@partners.org
Circulation
|June 22, 2005
Resumen
La pérdida tardía en el diámetro del lumen es un predictor confiable del riesgo de restenosis para los stents coronarios. Esta medida angiográfica ofrece un mayor poder estadístico que las tasas de restenosis tradicionales, especialmente para los nuevos stents de liberación de fármacos.
Área de la Ciencia:
- Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular
- Cardiología Intervencionista Cardiología intervencionista.
- Ingeniería Biomédica Ingeniería Biomédica.
Sus antecedentes:
- Las tasas de reestenosis coronaria han disminuido significativamente con los stents que emiten fármacos.
- Las evaluaciones tempranas del stent a menudo usan puntos finales continuos sustitutos.
- La generalizabilidad y el poder de estos puntos finales sustitutos requieren un examen sistemático.
Objetivo del estudio:
- Para evaluar la relación entre la pérdida tardía de luz y la probabilidad de restenosis.
- Para comparar el poder estadístico de la pérdida tardía de luz frente a la restenosis binaria.
- Para evaluar la pérdida tardía de lumen como un punto final para nuevos ensayos de stent.
Principales métodos:
- Análisis de los datos de pérdida tardía de luz de 22 ensayos de stent publicados.
- Incluye stents de metal desnudo, de liberación de drogas y de pequeños vasos sanguíneos.
- Comparación de la potencia entre las diferencias de pérdida tardía y las tasas de restenosis binaria.
Principales resultados:
- Se observó una relación lineal entre la pérdida tardía media y su desviación estándar, independientemente del tipo de stent o del diámetro del vaso.
- El aumento de la pérdida tardía de luz se asoció monotónicamente con un mayor riesgo de restenosis.
- La pérdida tardía de luz demostró un poder significativamente mayor para detectar los efectos del tratamiento en comparación con la restenosis binaria.
Conclusiones:
- La pérdida tardía de lumen es un punto final angiográfico generalizable y poderoso.
- Está fuertemente y monotónicamente relacionado con el riesgo de restenosis en varios tipos de stent.
- La pérdida tardía de lumen es particularmente valiosa para los primeros ensayos de nuevos stents de liberación de fármacos.
Videos de Conceptos Relacionados
01:30Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...